Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura.
Ojeda-Uribe, Mario; Federici, Laure; Wolf, Martine; Coppo, Paul; Veyradier, Agnes.
; 50(3): 733-5, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20609201
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.
Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
Current topics in primary immune thrombocytopenia.
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.
ITP and TTP: interpreting evidence in light of patient values.
Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant.
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).